Ilango Balakrishnan

This study investigates how differential phagocytosis induced by RT or anti-CD47 therapy affects macrophage activation states in gliomas, showing that combination therapy reduces tumor growth and induces distinct macrophage states.

This paper identifies CD99 as a therapeutic target in K27M+DMGs, showing that a novel anti-CD99 antibody reduces tumor growth and enhances radiation efficacy in preclinical models.

This study identifies CDK9 as a conserved dependency in Myc-driven medulloblastoma and shows that CDK9 inhibition disrupts Myc-driven transcriptional programs, leading to anti-tumor effects.

This study identifies PRMT5 as essential for pediatric high-grade glioma growth by maintaining tumor stem cells, showing that its inhibition reduces self-renewal and improves survival in preclinical models.